MedAdvisor (MDR) Earnings Call Presentation

Financial Performance - Group revenue declined by 360% year-over-year to $630 million due to US health program budget pressures, regulatory challenges, and evolving market dynamics[23, 29] - Gross profit decreased by 385% year-over-year to $329 million[29] - The company recognized a non-cash impairment of $465 million on US intangibles[23] - EBITDA was down by $139 million year-over-year, reaching ($107 million)[29] Strategic Decisions and Capital Position - The ANZ business was divested post year-end to Jonas Software for $350 million, with potential earn-outs of up to $735 million over three years[23] - As of July 9, the company had a net cash position of $165 million, excluding an $8 million holdback, and all debt was extinguished[23] - The company withdrew its FY26 revenue guidance due to prevailing short-term market uncertainty in the US[24] US Market Operations - US revenue declined by 360% year-over-year, mirroring the group's overall revenue decrease[39] - THRiV-powered programs contributed 31% of US revenue in FY25, exceeding the PCP (Prior Corresponding Period)[40] - The US program pipeline is valued at US$125 million (unweighted) heading into 1H FY26[24, 58] - Operating costs for continuing operations are expected to decrease by 10% in FY26 compared to FY25 due to right-sizing efforts[24, 59]